Deborah Anzalone

1.1k total citations
19 papers, 841 citations indexed

About

Deborah Anzalone is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Deborah Anzalone has authored 19 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 6 papers in Cardiology and Cardiovascular Medicine and 6 papers in Economics and Econometrics. Recurrent topics in Deborah Anzalone's work include Lipoproteins and Cardiovascular Health (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmaceutical Economics and Policy (4 papers). Deborah Anzalone is often cited by papers focused on Lipoproteins and Cardiovascular Health (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmaceutical Economics and Policy (4 papers). Deborah Anzalone collaborates with scholars based in United States, Germany and Australia. Deborah Anzalone's co-authors include Daniel E. Hilleman, James M. Backes, Bonita Falkner, DAVID C. CHAIKIN, Asnat Groutz, Jerry G. Blaivas, Neil M. Resnick, Efrain Reisin, Howard G. Hutchinson and Alan J. Wein and has published in prestigious journals such as Hypertension, The Journal of Urology and The American Journal of Cardiology.

In The Last Decade

Deborah Anzalone

19 papers receiving 818 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Anzalone United States 11 283 265 258 172 135 19 841
G Stein Germany 17 254 0.9× 82 0.3× 113 0.4× 43 0.3× 22 0.2× 58 1.2k
Matti Nikkilä Finland 14 263 0.9× 153 0.6× 251 1.0× 59 0.3× 11 0.1× 22 712
E. Valvo Italy 20 200 0.7× 302 1.1× 106 0.4× 29 0.2× 19 0.1× 61 1.0k
Mario De Michele Italy 13 161 0.6× 455 1.7× 163 0.6× 43 0.3× 17 0.1× 47 789
Megumu Fukunaga Japan 16 65 0.2× 134 0.5× 136 0.5× 27 0.2× 11 0.1× 34 844
Kenzo Oba Japan 14 379 1.3× 152 0.6× 172 0.7× 18 0.1× 7 0.1× 56 761
Augusto Antonello Italy 14 95 0.3× 157 0.6× 106 0.4× 13 0.1× 20 0.1× 41 679
Priscilla Zia United States 15 218 0.8× 122 0.5× 207 0.8× 29 0.2× 8 0.1× 22 1.2k
Murat Dursun Türkiye 16 151 0.5× 11 0.0× 98 0.4× 101 0.6× 145 1.1× 74 688
Emilio Nardi Italy 24 359 1.3× 1.1k 4.3× 186 0.7× 27 0.2× 6 0.0× 81 1.7k

Countries citing papers authored by Deborah Anzalone

Since Specialization
Citations

This map shows the geographic impact of Deborah Anzalone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Anzalone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Anzalone more than expected).

Fields of papers citing papers by Deborah Anzalone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Anzalone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Anzalone. The network helps show where Deborah Anzalone may publish in the future.

Co-authorship network of co-authors of Deborah Anzalone

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Anzalone. A scholar is included among the top collaborators of Deborah Anzalone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Anzalone. Deborah Anzalone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Cook, Erin, Jill Davis, Rubeen Israni, et al.. (2021). Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. Advances in Therapy. 38(10). 5238–5252. 5 indexed citations
2.
Israni, Rubeen, Keith A. Betts, Fan Mu, et al.. (2021). Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia. Advances in Therapy. 38(11). 5596–5608. 4 indexed citations
3.
Davis, Jill, Rubeen Israni, Keith A. Betts, et al.. (2021). Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis. Advances in Therapy. 39(2). 1033–1044. 5 indexed citations
4.
Lewis, Sandra, et al.. (2017). LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Current Medical Research and Opinion. 34(10). 1717–1723. 1 indexed citations
5.
Olufade, Temitope, Deborah Anzalone, David M. Kern, et al.. (2017). Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. Journal of the American Heart Association. 6(5). 24 indexed citations
6.
Backes, James M., et al.. (2016). The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids in Health and Disease. 15(1). 118–118. 141 indexed citations
7.
Nichols, Gregory A., Kristi Reynolds, Temitope Olufade, et al.. (2016). Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 119(3). 410–415. 7 indexed citations
8.
Vaziri, Nosratola D., et al.. (2016). Statins in Chronic Kidney Disease: When and When Not to Use Them.. PubMed. 65(8 Suppl). 2 indexed citations
9.
Johnston, Stephen S., John J. Sheehan, Ellen Riehle, et al.. (2015). Development and validation of a u.s. Administrative claims-based algorithm to classify patients with type 2 diabetes mellitus into renal impairment stages. Value in Health. 18(3). A10–A10. 2 indexed citations
10.
Zeeuw, Dick de, Deborah Anzalone, Valerie A. Cain, et al.. (2015). Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes & Endocrinology. 3(3). 181–190. 116 indexed citations
11.
Welty, Francine K., Sandra Lewis, Karen E. Friday, Valerie A. Cain, & Deborah Anzalone. (2015). A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study. Journal of Women s Health. 25(1). 50–56. 10 indexed citations
12.
Kern, David M., Sanjeev Balu, Ozgur Tunceli, & Deborah Anzalone. (2014). Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III. Current Medical Research and Opinion. 30(12). 2443–2451. 11 indexed citations
13.
14.
Goldstein, Barry J., Julio Rosenstock, Deborah Anzalone, Conrad Tou, & K. Peter Öhman. (2006). Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trial. Current Medical Research and Opinion. 22(12). 2575–2590. 56 indexed citations
15.
Rodby, Roger A., Richard D. Rohde, William R. Clarke, et al.. (2000). The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation. 15(4). 487–497. 103 indexed citations
16.
Groutz, Asnat, Jerry G. Blaivas, DAVID C. CHAIKIN, et al.. (2000). NONINVASIVE OUTCOME MEASURES OF URINARY INCONTINENCE AND LOWER URINARY TRACT SYMPTOMS: A MULTICENTER STUDY OF MICTURITION DIARY AND PAD TESTS. The Journal of Urology. 164(3 Part 1). 698–701. 148 indexed citations
17.
Groutz, Asnat, Jerry G. Blaivas, DAVID C. CHAIKIN, et al.. (2000). NONINVASIVE OUTCOME MEASURES OF URINARY INCONTINENCE AND LOWER URINARY TRACT SYMPTOMS: A MULTICENTER STUDY OF MICTURITION DIARY AND PAD TESTS. The Journal of Urology. 698–701. 39 indexed citations
18.
Reisin, Efrain, et al.. (1997). Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients. Hypertension. 30(1). 140–145. 123 indexed citations
19.
Falkner, Bonita, Mitzy Canessa, & Deborah Anzalone. (1995). Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. American Journal of Hypertension. 8(5). 454–460. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G Stein Breakdown of academic impact, for papers by Matti Nikkilä Breakdown of academic impact, for papers by E. Valvo Breakdown of academic impact, for papers by Mario De Michele Breakdown of academic impact, for papers by Megumu Fukunaga Breakdown of academic impact, for papers by Kenzo Oba Breakdown of academic impact, for papers by Augusto Antonello Breakdown of academic impact, for papers by Priscilla Zia Breakdown of academic impact, for papers by Murat Dursun Breakdown of academic impact, for papers by Emilio Nardi
Rankless by CCL
2026